Research & Development

We are developing a first-in-class bi-functional antibody therapy to address blood cancer indications with high unmet medical needs.

read more



We have forged world class alliances that combine the strengths, expertise and resources of our industry and academic collaborators into one focused and integrated network, committed and passionate about developing the best, most innovative therapy for patients.

read more

Healthy stock market


Amphivena Therapeutics, Inc., which began operations in July 2013, is a preclinical stage company based in San Francisco, California developing innovative therapies for hematologic malignancies.

read more

About Amphivena

Restoring the flow of life

Our mission is to eradicate blood cancers with a breakthrough therapy that harnesses the patient’s own immune system to destroy tumor cells and their precursors. Our aim is to restore the cellular balance needed for proper blood formation, function and circulation, restoring the flow of life to patients that face life threatening illnesses.

read more

Latest News

  1. In vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs

    May 30, 2015

  2. Development Of A Bispecific Tetravalent CD33/CD3 TandAb For The Treatment of AML

    May 31, 2015